Founded in 2012 by pioneers in rapid diagnostics, NG Biotech is a fully integrated diagnostics company specializing in lateral flow technologies.

The company designs, develops, and manufactures innovative diagnostic solutions, with end-to-end control spanning from early research and development through clinical validation and large-scale industrial deployment.

Headquartered and manufacturing in France, NG Biotech operates to the highest standards of clinical performance, quality assurance, and regulatory compliance, serving healthcare systems and partners worldwide.

NG Biotech is advancing the future of diagnostics by addressing critical unmet needs in the detection of antimicrobial resistance, emerging infectious diseases, and women’s health. Through a new generation of rapid, reliable, and multiplex diagnostic tests, the company enables timely, actionable clinical decision-making where it has the greatest impact.

Aurora makes breakthrough low-temperature sterilizers for sensitive medical devices.

The sterilant is made of pure air gases, turned into plasmas (= northern lights). This technology paves the way to:
– the sterile reprocessing of complex medical devices in hospitals: GI endoscopes and echo-endoscopic probes
– environmentally friendly sterilization of medical devices manufactured by large medtech manufacturers

The company has been largely recognized for its unique technology and potential, as a France 2030 AMI-MIE, EIC Accelerator, and IPCEI Tech4Cure laureate.

Aurora’s first sales highlight strong market traction, and the company expects even stronger momentum with CE marking expected in Q4 2026 and FDA approval by the end of 2026. This is why Aurora is aiming to raise capital by the end of this year to support its growth.